P71 iPSCs 1

General#

Cell Line

hPSCreg Name IBPi002-A
Alternative name(s)
P71 iPSCs 1
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 22nd October 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Institute of Biophysics of the Czech Academy of Sciences (IBP)
Distributors
Derivation country Czech Republic

External Databases

BioSamples SAMEA4867771
Cellosaurus CVCL_VL45

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research: allowed
Clinical: not allowed
Commercial: not allowed

Donor Information#

General Donor Information

Sex male
Age of donor (at collection) 65-69
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
prostate adenocarcinoma
Synonyms
  • Neoplasm, Prostate
  • Cancer, Prostate
  • Adenocarcinoma of the Prostate
  • PROSTATIC NEOPL
  • Prostate Neoplasms
  • Adenocarcinoma of prostate (disorder)
  • Prostatic Neoplasms
  • Cancers, Prostatic
  • NEOPL PROSTATIC
  • NEOPL PROSTATE
  • Prostate Neoplasm
  • Prostatic Neoplasm
  • Cancer of the Prostate
  • Neoplasms, Prostate
  • Prostatic Cancer
  • Neoplasm, Prostatic
  • Prostatic Cancers
  • PROSTATE NEOPL
  • adenocarcinoma of prostate
  • Cancer of Prostate
  • Prostate Cancer
  • Cancer, Prostatic
  • Cancers, Prostate
  • Neoplasms, Prostatic
  • Prostate Cancers
  • adenocarcinoma of the prostate
  • prostate gland adenocarcinoma
  • prostate adenocarcinoma
show more synonyms
Is the medical history available upon request? yes
Is clinical information available? yes

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA4892803

Ethics#

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent development of commercial products? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? ethics committee of Palacky University, Olomouc; Czech Republic approval nr. 127/14 and 163/08
Approval number 127/14, 163/08
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? ethics committee of Palacky University, Olomouc; Czech Republic approval nr. 127/14 and 163/08
Approval number 127/14, 163/08
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation#

General

Source cell line name prostate cancer associated fibroblasts P71
Source cell type
fibroblast
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.
Source cell origin
prostate adenocarcinoma
An adenocarcinoma arising from the prostate gland. It is one of the most common malignant tumors afflicting men. The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland. Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival. Several grading systems have been proposed, of which the Gleason system is the most commonly used. Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.; A carcinoma that arises from glandular epithelial cells of the prostate gland; Tumors or cancer of the PROSTATE.
Synonyms
  • Neoplasm, Prostate
  • Cancer, Prostate
  • Adenocarcinoma of the Prostate
  • PROSTATIC NEOPL
  • Prostate Neoplasms
  • Adenocarcinoma of prostate (disorder)
  • Prostatic Neoplasms
  • Cancers, Prostatic
  • NEOPL PROSTATIC
  • NEOPL PROSTATE
  • Prostate Neoplasm
  • Prostatic Neoplasm
  • Cancer of the Prostate
  • Neoplasms, Prostate
  • Prostatic Cancer
  • Neoplasm, Prostatic
  • Prostatic Cancers
  • PROSTATE NEOPL
  • adenocarcinoma of prostate
  • Cancer of Prostate
  • Prostate Cancer
  • Cancer, Prostatic
  • Cancers, Prostate
  • Neoplasms, Prostatic
  • Prostate Cancers
  • adenocarcinoma of the prostate
  • prostate gland adenocarcinoma
  • prostate adenocarcinoma
show more synonyms
Source cell type (free text) prostate cancer-associated fibroblasts
Age of donor (at collection) 65-69
Collected in 2011

Reprogramming method

Vector type Non-integrating
Vector Episomal
Is reprogramming vector detectable?
No
Methods used
PCR
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Other

Selection criteria for clones morphology
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Vitronectin
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
NANOG
Yes
SOX2
Yes
POU5F1 (OCT-4)
Yes
TRA 1-60
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
45,X
Karyotyping method: G-Banding

Other Genotyping (Cell Line)